This week, Peter Simons covers a study that found prolactin-increasing antipsychotics associated with increased breast cancer risk, an analysis that found no convincing evidence that screening for depression improves outcomes, and the continuing controversy around the FDA's approval of Biogen's failed Alzheimer's drug aducanumab.

• Antipsychotics Linked to Increased Breast Cancer Risk
• Screening for Depression in Primary Care Does Not Improve Outcomes
• Alzheimer’s Drug Controversy Continues